Absence of infective endocarditis relapse when end-of-treatment fluorodeoxyglucose positron emission tomography/computed tomography is negative.


Journal

European heart journal. Cardiovascular Imaging
ISSN: 2047-2412
Titre abrégé: Eur Heart J Cardiovasc Imaging
Pays: England
ID NLM: 101573788

Informations de publication

Date de publication:
27 10 2023
Historique:
received: 25 02 2023
revised: 19 04 2023
accepted: 14 05 2023
medline: 30 10 2023
pubmed: 12 6 2023
entrez: 12 6 2023
Statut: ppublish

Résumé

In non-operated infective endocarditis (IE), relapse may impair the outcome of the disease. The aim of the study was to evaluate the relationship between end-of-treatment (EOT) fluorodeoxyglucose positron emission tomography/computed tomography FDG-PET/CT results and relapse in non-operated IE either on native or prosthetic valve. We included 62 patients who underwent an EOT FDG-PET/CT for non-operated IE performed between 30 and 180 days of antibiotic therapy initiation. Qualitative valve assessment categorized initial and EOT FDG-PET/CT as negative or positive. Quantitative analyses were also conducted. Clinical data from medical charts were collected, including endocarditis team decision for IE diagnosis and relapse. Forty-one (66%) patients were male with a median age of 68 years (57; 80) and 42 (68%) had prosthetic valve IE. End-of-treatment FDG-PET/CT was negative in 29 and positive in 33 patients. The proportion of positive scans decreased significantly compared with initial FDG-PET/CT (53% vs. 77%, respectively, P < 0.0001). All relapses (n = 7, 11%) occurred in patients with a positive EOT FDG-PET/CT with a median delay after EOT FDG-PET/CT of 10 days (0; 45). The relapse rate was significantly lower in negative (0/29) than in positive (7/33) EOT FDG-PET/CT (P = 0.01). In this series of 62 patients with non-operated IE who underwent EOT FDG-PET/CT, those with a negative scan (almost half of the study population) did not develop IE relapse after a median follow-up of 10 months. These findings need to be confirmed by prospective and larger studies.

Identifiants

pubmed: 37307564
pii: 7194662
doi: 10.1093/ehjci/jead138
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D
Radiopharmaceuticals 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1480-1488

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Déclaration de conflit d'intérêts

Conflict of interest: None declared.

Auteurs

Claudine Régis (C)

Nuclear Medicine Department, Hôpital Bichat-Claude Bernard, AP-HP, 46 rue Henri-Huchard, Paris 75018, France.
Department of Medical Imaging, Institut de cardiologie de Montréal, Université de Montréal, 5000 rue Bélanger, Montréal, Québec H1T 1C8, Canada.

Michael Thy (M)

Infectious Disease Department, Hôpital Bichat-Claude Bernard, AP-HP, 46 rue Henri-Huchard, Paris 75018, France.
Université Paris Cité, 45 Rue des Saints-Pères, Paris 75006, France.

Besma Mahida (B)

Nuclear Medicine Department, Hôpital Bichat-Claude Bernard, AP-HP, 46 rue Henri-Huchard, Paris 75018, France.
Laboratory for Vascular Translational Science, Inserm U1148, 46 rue Henri-Huchard, Paris 75018, France.

Laurène Deconinck (L)

Infectious Disease Department, Hôpital Bichat-Claude Bernard, AP-HP, 46 rue Henri-Huchard, Paris 75018, France.

Sarah Tubiana (S)

Université Paris Cité, 45 Rue des Saints-Pères, Paris 75006, France.
Clinical Investigation Center, Hôpital Bichat-Claude Bernard, AP-HP, 46 rue Henri-Huchard, Paris 75018, France.

Bernard Iung (B)

Université Paris Cité, 45 Rue des Saints-Pères, Paris 75006, France.
Laboratory for Vascular Translational Science, Inserm U1148, 46 rue Henri-Huchard, Paris 75018, France.
Cardiology Department, Hôpital Bichat-Claude Bernard, AP-HP, 46 rue Henri-Huchard, 75018, 46 rue Henri-Huchard, Paris 75018, France.

Xavier Duval (X)

Université Paris Cité, 45 Rue des Saints-Pères, Paris 75006, France.
Clinical Investigation Center, Hôpital Bichat-Claude Bernard, AP-HP, 46 rue Henri-Huchard, Paris 75018, France.

François Rouzet (F)

Nuclear Medicine Department, Hôpital Bichat-Claude Bernard, AP-HP, 46 rue Henri-Huchard, Paris 75018, France.
Université Paris Cité, 45 Rue des Saints-Pères, Paris 75006, France.
Laboratory for Vascular Translational Science, Inserm U1148, 46 rue Henri-Huchard, Paris 75018, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH